前列腺癌男性中促性腺激素释放激素拮抗剂与激动剂的心血管风险:台湾一项观察性研究
该研究基于台湾人群数据库,比较促性腺激素释放激素(GnRH)拮抗剂(地加瑞克,n=499)与GnRH激动剂(戈舍瑞林、亮丙瑞林、曲普瑞林,n=15,127)治疗前列腺癌患者的心血管疾病风险。在已有心血管疾病的患者中,GnRH拮抗剂组的复合心血管事件风险和主要不良心血管事件(MACE)风险均低于GnRH激动剂组。
要点
- GnRH拮抗剂组所有患者的复合心血管事件风险低于GnRH激动剂组。
- 已有心血管疾病患者中,GnRH拮抗剂组MACE风险降低33%(aHR 0.67)。
- 已有心血管疾病患者中,GnRH拮抗剂组复合心血管事件风险降低84%(aHR 0.16)。
核心结论
- 在前列腺癌且已有心血管疾病的患者中,与GnRH激动剂相比,使用GnRH拮抗剂与更低的复合心血管事件风险和MACE风险相关。
研究设计与样本
- 基于台湾人群数据库的观察性研究,比较GnRH拮抗剂(地加瑞克;n=499)与GnRH激动剂(戈舍瑞林、亮丙瑞林、曲普瑞林;n=15,127)治疗的前列腺癌患者。
- 评估雄激素剥夺治疗开始后≥90天发生的MACE(缺血性心脏病、卒中、充血性心力衰竭或全因死亡)和复合心血管事件(缺血性心脏病、卒中、充血性心力衰竭或心血管死亡)。
- 已有心血管疾病定义为ADT开始前一年内因缺血性心脏病接受心脏治疗、报告卒中或充血性心力衰竭。
- 调整年龄、基线糖尿病、高血压状态及所接受治疗后获得调整风险比(aHR)和95%置信区间(CI)。
主要发现
- 所有接受GnRH拮抗剂治疗的患者复合心血管事件风险均低于接受GnRH激动剂治疗的患者。
- 诊断时已有转移的患者中,GnRH拮抗剂与更低的复合心血管事件风险相关(aHR 0.16;95% CI,0.04-0.38;p=0.013)。
- 接受ADT超过六个月的患者中,GnRH拮抗剂与更低的复合心血管事件风险相关(aHR 0.30;95% CI,0.16-0.54;p<0.0001)。
- 已有心血管疾病的患者中,GnRH拮抗剂组较GnRH激动剂组MACE风险降低33%(aHR 0.67;95% CI,0.46-0.96;p=0.0299)。
- 已有心血管疾病的患者中,GnRH拮抗剂组较GnRH激动剂组复合心血管事件风险降低84%(aHR 0.16;95% CI,0.05-0.50;p=0.0017)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of gonadotropin-releasing hormone (GnRH) antagonist and agonist (GnRHa) treatment on cardiovascular disease (CVD) risk in prostate cancer (PCa) remains inconclusive due to conflicting findings. We compared the effects of GnRH antagonist and GnRHa treatments on CVD risk in patients with PCa and pre-existing CVD, in a Taiwan population-based database. METHODS: We assessed the risk of major adverse CV events (MACE: ischemic heart disease [IHD], stroke, congestive heart failure [CHF] or all cause deaths) and composite CV events (IHD, stroke, CHF or CV deaths) occurring ≥90 days after androgen deprivation therapy (ADT) initiation in patients with PCa after 90 days of treatment with either GnRH antagonist (degarelix; n = 499) or GnRHa (goserelin, leuprolide, triptorelin; n = 15,127). Patients identified with pre-existing CVD had received cardiac therapy for IHD, reported a stroke or CHF within a year before ADT initiation. Adjusted hazard ratios (aHR) and 95% confidence interval (CI) were obtained for MACE and composite CV events risk after adjusting for age, baseline status of diabetes, hypertension and treatments received. RESULTS: All GnRH antagonist-treated patients showed lower risk of composite CV events than the GnRHa-treated patients. The lower composite CV events risk associated with GnRH antagonist was also observed in patients with metastasis at diagnosis (aHR 0.16; 95% CI, 0.04-0.38; p = 0.013) and those receiving ADT for more than six months (aHR 0.30; 95% CI, 0.16-0.54; p < 0.0001). In patients with pre-existing CVD, the MACE risk was 33% lower (aHR 0.67; 95% CI, 0.46-0.96; p = 0.0299) and composite CV events risk was 84% lower (aHR 0.16; 95% CI, 0.05-0.50; p = 0.0017) in GnRH antagonist-treated than the GnRHa-treated patients. CONCLUSIONS: In patients with PCa and pre-existing CVD, GnRH antagonist use was associated with lower risks for composite CV events and MACE compared with GnRHa.
引用
- Shao YJ, Hong JH, Chen CK, et al. Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan. Prostate Cancer Prostatic Dis. 2022. PMID: 35662291. doi:10.1038/s41391-022-00555-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。